VIRX Stock Overview
Viracta Therapeutics, Inc., a clinical-stage precision oncology company, focuses on the treatment and prevention of virus-associated cancers that impact patients worldwide.
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Viracta Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.85 |
| 52 Week High | US$2.38 |
| 52 Week Low | US$0.43 |
| Beta | 0.36 |
| 1 Month Change | -20.02% |
| 3 Month Change | 68.25% |
| 1 Year Change | -32.71% |
| 3 Year Change | -91.43% |
| 5 Year Change | n/a |
| Change since IPO | -93.72% |
Recent News & Updates
Shareholder Returns
| VIRX | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -9.4% | 1.5% | 1.2% |
| 1Y | -32.7% | 1.1% | 24.7% |
Return vs Industry: VIRX underperformed the US Biotechs industry which returned 1.1% over the past year.
Return vs Market: VIRX underperformed the US Market which returned 24.7% over the past year.
Price Volatility
| VIRX volatility | |
|---|---|
| VIRX Average Weekly Movement | 18.5% |
| Biotechs Industry Average Movement | 11.7% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.6% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: VIRX's share price has been volatile over the past 3 months.
Volatility Over Time: VIRX's weekly volatility (19%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | 40 | Mark Rothera | www.viracta.com |
Viracta Therapeutics, Inc., a clinical-stage precision oncology company, focuses on the treatment and prevention of virus-associated cancers that impact patients worldwide. Its lead product candidate is Nana-val, an all-oral combination therapy of its proprietary investigational drug, nanatinostat, and the antiviral agent valganciclovir. The company’s Nana-val is in various ongoing clinical trials, including NAVAL-1, an open-label Phase 2 basket trial for the treatment of multiple subtypes of relapsed/refractory Epstein-Barr virus-positive (EBV+) lymphoma, as well as an open-label Phase 1b/2 trial for the treatment of EBV+ recurrent or metastatic nasopharyngeal carcinoma and other EBV+ solid tumors.
Viracta Therapeutics, Inc. Fundamentals Summary
| VIRX fundamental statistics | |
|---|---|
| Market cap | US$33.30m |
| Earnings (TTM) | -US$51.06m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-0.7x
P/E RatioIs VIRX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| VIRX income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$51.06m |
| Earnings | -US$51.06m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.30 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 138.0% |
How did VIRX perform over the long term?
See historical performance and comparison